Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Rigshospitalet, Denmark
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05095857CT.gov The Anaesthetic Ketamine as Treatment for Patients With Severe Acute Brain Injury | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Intracerebral Hemorrhage
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Jnj-54135419 (this asset) | Rigshospitalet, Denmark | Approved | B · 62 |
| Edoxaban | Population Health Research Institute | P4 | BBB |
| Tranexamic Acid | Christian Medical College and Hospital, Ludhiana, India | P4 | BB |
| Aspirin | University Hospital, Lille | P4 | BB |
| Rivaroxaban | Imperial College London | P3 | BB |
| Tenecteplase | Gaurav Gupta, MD | P3 | BB |
| Propofol | Henry M. Jackson Foundation for the Advancement of Military Medicine | P4 | BB |
| Dexmedetomidine | Henry M. Jackson Foundation for the Advancement of Military Medicine | P4 | BB |
| Midazolam | Henry M. Jackson Foundation for the Advancement of Military Medicine | P4 | BB |
+42 more in the Intracerebral Hemorrhage cohort
Other indications for Jnj-54135419
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Depressive Disorder | — | P4 | BBB · 75 |
| Chronic Pain Syndrome | — | P4 | BBB · 73 |
| Major Depressive Disorder | — | P4 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Jnj-54135419 in Intracerebral Hemorrhage. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/jnj-54135419-intracerebral-hemorrhage
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →